NovaBay Pharmaceuticals Reports Activity of New Drug Against Deadly “Superbug”

NovaBay recently announced that in tests conducted at a third-party laboratory, its experimental drug NVC-422 showed in vitro activity against NDM-1. - January 13, 2011

NovaBay Pharmaceuticals Featured in November/December Issue of PharmaVOICE

Company Executives Offer “Crystal Ball” Predictions. VP of Research Discusses Need for New Approaches in Anti-Infectives. - November 22, 2007

NovaBay Pharmaceuticals, Inc. Retains The Investor Relations Group of New York

IRG to Communicate the Company’s Clinical Development Programs - November 21, 2007

Press Releases 1 - 3 of 3